The dramatic therapeutic responses that have been achieved in patients with leukemia, lymphoma, and certain other tumors have led to increased anticipation for the treatment of all patients with malignant disease. While major developments have occurred in different areas of clinical oncology, this past year has been characterized as one of direct clinical application of advances in basic science and technology. In addition, the lessons learned from the treatment of one type of cancer have been incorporated into the management of other forms of malignant neoplasms.
The ability to diagnose, stage, and monitor malignant disease accurately is an essential part of the care of patients with cancer. Recent progress in this area has been made with the use of radiolabeled antibodies to specific tumor markers. Historically, the detection and serological quantitation of selected tumor-markers have proved to be of limited clinical value because of lack of specificity and